Anson Funds Management LP Purchases 398,431 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)

Anson Funds Management LP raised its stake in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Free Report) by 50.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,192,266 shares of the company's stock after purchasing an additional 398,431 shares during the quarter. Anson Funds Management LP owned 1.69% of SELLAS Life Sciences Group worth $1,240,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in SLS. Virtu Financial LLC raised its holdings in SELLAS Life Sciences Group by 24.1% during the 3rd quarter. Virtu Financial LLC now owns 79,241 shares of the company's stock valued at $99,000 after buying an additional 15,398 shares during the last quarter. Northern Trust Corp raised its stake in shares of SELLAS Life Sciences Group by 33.6% during the fourth quarter. Northern Trust Corp now owns 134,721 shares of the company's stock valued at $140,000 after acquiring an additional 33,878 shares during the last quarter. State Street Corp boosted its holdings in shares of SELLAS Life Sciences Group by 30.2% during the third quarter. State Street Corp now owns 174,529 shares of the company's stock worth $218,000 after purchasing an additional 40,500 shares during the period. Opus Capital Group LLC grew its stake in shares of SELLAS Life Sciences Group by 5.5% in the fourth quarter. Opus Capital Group LLC now owns 238,500 shares of the company's stock worth $248,000 after purchasing an additional 12,400 shares during the last quarter. Finally, Brooklyn FI LLC purchased a new position in SELLAS Life Sciences Group during the 4th quarter valued at about $677,000. Hedge funds and other institutional investors own 17.38% of the company's stock.

SELLAS Life Sciences Group Price Performance

SLS traded down $0.01 during midday trading on Thursday, reaching $1.70. 1,892,370 shares of the company's stock traded hands, compared to its average volume of 1,390,495. SELLAS Life Sciences Group, Inc. has a 52 week low of $0.77 and a 52 week high of $1.85. The firm has a fifty day moving average of $1.25 and a two-hundred day moving average of $1.18. The stock has a market capitalization of $161.06 million, a price-to-earnings ratio of -2.47 and a beta of 2.34.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last announced its quarterly earnings results on Thursday, March 20th. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.03. During the same period in the previous year, the business posted ($1.34) earnings per share. Sell-side analysts forecast that SELLAS Life Sciences Group, Inc. will post -0.57 EPS for the current year.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.